Over time, the field of genetic testing for many cancer biomarkers, such as breast cancer driver genes BRCA1 and BRCA2, improved, starting from single gene sequencing on sanger sequencing technology, followed by multigene panels, which were created as a result of developments in next-generation sequencing technology (NGS), allowing for a broader genetic assessment, a faster testing method, and better throughput, without being cost prohibitive but constrained by the generation of short reads [1,2]. This evidence concerns the gene BRCA1 and breast carcinoma.